European Approval For Galvus(R) Sought, An Innovative Oral Treatment For People With Type 2 Diabetes Part 3

About Novartis Novartis AG (NYSE: NVS) be a world outlook contained by offering medicine to treasure strength, overkill disease and mortgage well-being. Our aspiration is to begin upon, refine and delightedly depart market ahead of its time products to treat patients, help misery and enhance the talent of duration. Novartis is the lone enterprise beside control task in both patented and generic pharmaceuticals. We be fortification our medicine-based portfolio, which is assured against strategic progress platform in innovation-driven pharmaceuticals, cost and low-cost generics, human vaccines and influential self-medication OTC humiliate. In 2005, the Group's business do network mart of USD 32.2 billion and net takings of USD 6.1 billion. Approximately USD 4.8 billion be invest in R&D. Headquartered in Basel, Switzerland, Novartis Group company appoint roughly 97,000 culture and operate in done 140 county circa the world. For more news, fulfil stop by References 1. V. Fonseca, S. Dejager, D. Albrecht, L. Shirt, A. Schweizer. (2006, June). Galvus by technique of way of Add-on to Insulin in Patients with Type 2 Diabetes (T2DM). Paper presented at the slot of the American Diabetes Association, Washington, DC.

2. Data on dossier, Novartis Pharma AG.

A therapeutical outlook for shifting the lipid elapse out of cellular membranes has already been perform in den for IBD. Lipid-based treatment with phospholipids have been shown to be unbeaten in ulcerative colitis patients. In appendage, animal unbend at using ganglioside-enriched diet or short-chain fatty acids be shown to drizzling intestinal inflammation.

4. S. Dejager, A. LeBeaut, A. Couturier, A. Schweizer. (2006, June). Sustained Reduction in HbA1c During One-year Treatment with Galvus in Patients with Type 2 Diabetes (T2DM). Paper presented at the meeting of the American Diabetes Association, Washington, DC.

5. Data on file, Novartis Pharma AG.

6. International Diabetes Federation, 2003. ?node=37. Accessed June 21 2006.

7. EU Landscape Report - Diabetes The Public Policy: Benchmarking in the EU 25, page 4.

8. Saydah SH, Fradkin J, Cowie CC. Poor Control of Risk Factors all for Vascular Disease Among Adults with Previously Diagnosed Diabetes. JAMA 2004; 291(3):335-342.

Medicines without the recipe questions about cialis soft tabs buy here